Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company that develops ultra-tunable peptide therapeutics designed to target intracellular proteins that have historically been considered undruggable. The organization utilizes its proprietary Helicon peptide platform to engineer stabilized helical peptides that combine the cell permeability and tissue distribution of small molecules with the high specificity and binding capabilities of antibodies. These therapies are applied to address serious conditions such as cancer, using an approach that inhibits challenging protein-protein and protein-DNA interactions as well as executing targeted protein degradation.

To support its research and therapeutic development, Parabilis Medicines employs an artificial intelligence- and simulation-enabled Helicon platform. This computational approach allows the company to manage the astronomical diversity of non-canonical amino acids and modify the chemical and biological properties of its peptide candidates. The platform facilitates target identification, credentialing, and lead optimization by integrating internal and external datasets to establish biological rationale, mechanism of action, and disease context.

The open roles indicate that Parabilis Medicines builds specialized scientific teams focused on translational data science and computational biology. The current hiring needs include senior scientific leadership roles, such as a Principal Scientist in Translational Data Science based in Cambridge, which requires expertise in computational biology and oncology biology to drive preclinical projects from target identification through lead optimization.